tirzepatide clinical trials SURMOUNT-3 study design This is a phase 3, multicenter, randomized, FDA Approves Tirzepatide, A Potential

This question is becoming more relevant as clinicians encounter variability in outcomes

These are only theories , and there is no direct evidence yet to support them

In parallel, mitochondrial injury promotes inflammatory amplification through the release of DAMPs, activation of inflammasome-related pathways, and propagation of sterile inflammatory signaling within the pancreas and beyond

In this survey, patients were asked to rate 54 symptoms, and based on their responses we characterized them into 6 groups: fatigue (I), malaise (II), sleep difficulties (III), pain (IV), cognitive/neurological manifestations (V), and other (VI) which included autonomic, neuroendocrine, and immune manifestations